23 Oct 2026
byDr. David Sing-Ngai Cheung, Specialist in Neurology, Member of the Hong Kong Headache Society
Migraine is a primary headache disorder with disabling episodic attacks, affecting around 12.5 percent of Hong Kong’s population. Important gaps in local migraine management include underuse of preventive therapy, delayed specialist referral and medication overuse. In an interview with MIMS Doctor, Dr David Sing-Ngai Cheung, Specialist in Neurology and a member of the Hong Kong Headache Society, discussed how calcitonin gene-related peptide (CGRP)–targeted therapies, particularly gepants, support earlier intervention and potentially improve outcomes of patients with migraine while offering favourable tolerability and safety.